Active, not recruitingPhase 2NCT05031780
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Agios Pharmaceuticals, Inc.
- Intervention
- Mitapivat(drug)
- Enrollment
- 286 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2022 – 2025
Study locations (20)
- University of California San Diego, La Jolla, California, United States
- UCLA Health, Los Angeles, California, United States
- Children's Hospital Oakland, Oakland, California, United States
- University of Connecticut Health Center, Farmington, Connecticut, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
- Sylvester Comprehensive Cancer Center-Miami, Miami, Florida, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Riley Hospital For Children, Indianapolis, Indiana, United States
- LSU Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
- National Heart Lung and Blood Institute, Bethesda, Maryland, United States
- Kaiser Permanente - Largo Medical Center, Largo, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Boston Medical Center & Boston University School of Medicine, Boston, Massachusetts, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05031780 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi